Holly A. Swartz, M.D.
Trisha Suppes, M.D., Ph.D.
Books published by American Psychiatric Association Publishing represent the findings, conclusions, and views of the individual authors and do not necessarily represent the policies and opinions of American Psychiatric Association Publishing or the American Psychiatric Association.
Names: Swartz, Holly A., editor. | Suppes, Trisha, editor. | American Psychiatric Association Publishing, issuing body.
Title: Bipolar II disorder : recognition, understanding, and treatment / edited by Holly A. Swartz, Trisha Suppes.
Description: First edition. | Washington, D.C. : American Psychiatric Association Publishing, [2019] | Includes bibliographical references and index. |
Identifiers: LCCN 2019011723 (print) | LCCN 2019012924 (ebook) | ISBN 9781615372591 () | ISBN 9781615371785 (pbk. : alk. paper)
Classification: LCC RC516 (ebook) | LCC RC516 (print) | NLM WM 171.7 | DDC 616.89/5—dc23
A CIP record is available from the British Library.
To Steven, Sophie, and Eli—each special, for different reasons.
H.A.S.
To my sisters and brothers Deborah, John, Alexandra, and Michael with great appreciation you are in my life.
T.S.
To our patients and colleagues who taught us about bipolar II disorder; you made this book possible.
Contents
Contributors
Preface
Holly A. Swartz, M.D., and Trisha Suppes, M.D., Ph.D.
Part I
Recognition
1 A Neglected Condition
Holly A. Swartz, M.D., and Trisha Suppes, M.D., Ph.D.
2 Diagnosing Bipolar II Disorder
Nicole Kramer, M.A., M.S., and Trisha Suppes, M.D., Ph.D.
3 Interface Between Borderline Personality Disorder and Bipolar II Disorder
Mark Zimmerman, M.D., and Theresa A. Morgan, Ph.D.
4 Psychiatric and Medical Comorbidities With Bipolar II Disorder
Joshua D. Rosenblat, M.D., Michael J. Ostacher, M.D., M.P.H., M.M.Sc., and Roger S. McIntyre, M.D., F.R.C.P.C.
5 Suicide and Bipolar II Disorder
Ayal Schaffer, M.D., F.R.C.P.C., and
Mark Sinyor, M.Sc., M.D., F.R.C.P.C.
Part II
Understanding
6 Genetics of Bipolar II Disorder
Melvin McInnis, M.D.
7 Functional Brain Imaging and Neural Determinants in Bipolar II Disorder
Anna Manelis, Ph.D., Adriane M. Soehner, Ph.D., and
Mary L. Phillips, M.D., M.D.(Cantab.)
Part III
Treatment
8 Mood Stabilizers and Antipsychotic Medications in Bipolar II Disorder
Eva Solé, M.D., Marina Garriga, M.D., and
Eduard Vieta, M.D., Ph.D.
9 Antidepressant Medications in Bipolar II Disorder
Susan L. McElroy, M.D., and Alex Israel, M.D.
10 Psychosocial Interventions in Bipolar II Disorder
Danielle M. Novick, Ph.D., and Holly A. Swartz, M.D.
Part IV
Special Populations
11 Bipolar II Disorder in Childhood and Adolescence
Manivel Rengasamy, M.D., and Boris Birmaher, M.D.
12 Reproductive-Age Women With Bipolar II Disorder
Eydie L. Moses-Kolko, M.D., Crystal T. Clark, M.D., M.Sc.,
Sarah DeBrunner, M.D., and Katherine L. Wisner, M.D., M.S.
Index
Contributors
Boris Birmaher, M.D.
Professor of Psychiatry and Endowed Chair in Early Bipolar Disorder, Director of the Child and Adolescent Bipolar Services Program, Co-Director of Psychiatry Research Pathway Program, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Crystal T. Clark, M.D., M.Sc.
Assistant Professor of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Asher Center for the Study and Treatment of Depressive Disorders, Northwestern Feinberg School of Medicine, Chicago, Illinois
Sarah DeBrunner, M.D.
Clinical Assistant Professor, University of Pittsburgh School of Medicine, Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Marina Garriga, M.D.
Psychiatrist, Department of Psychiatry and Psychology, Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
Alex Israel, M.D.
Graduate Medical Resident in Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Nicole Kramer, M.A., M.S.
Doctoral Candidate and Research Assistant, Prevention and Intervention Laboratory, Stanford University School of Medicine, Stanford, California
Anna Manelis, Ph.D.
Assistant Professor, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Susan L. McElroy, M.D.
Chief Research Officer, Lindner Center of HOPE, Mason, Ohio; Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
Melvin McInnis, M.D.
Thomas B. and Nancy Upjohn Woodworth Professor of Bipolar Disorder and Depression, Professor of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan
Roger S. McIntyre, M.D., F.R.C.P.C.
Professor of Psychiatry and Pharmacology, University of Toronto; University Health Network, Mood Disorder Psychopharmacology Unit (MDPU), Toronto, ON, Canada
Theresa A. Morgan, Ph.D.
Clinical Assistant Professor of Psychiatry, Brown University; Staff Psychologist, Rhode Island Hospital, Providence, Rhode Island
Eydie L. Moses-Kolko, M.D.
Associate Professor of Psychiatry, University of Pittsburgh School of Medicine, Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Danielle M. Novick, Ph.D.
Clinical Psychologist, Outpatient Mood Disorders Clinic, Clinical Supervisor, Clinical Training Committee, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
Michael J. Ostacher, M.D., M.P.H., M.M.Sc.
Associate Professor of Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine; Medical Director, VA/Stanford Bipolar and Depression Research Program, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
Mary L. Phillips, M.D., M.D.(Cantab.)
Pittsburgh Foundation-Emmerling Endowed Chair in Psychotic Disorders, Professor in Psychiatry and Clinical and Translational Science, and Director of the Mood and Brain Laboratory, The Clinical and Translational Affective Neuroscience Program, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Manivel Rengasamy, M.D.
Child Psychiatry Fellow, Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Joshua D. Rosenblat, M.D.
Chief Resident of Psychiatry, Clinician Scientist Program, University of Toronto; University Health Network, Mood Disorder Psychopharmacology Unit (MDPU), Toronto, ON, Canada
Ayal Schaffer, M.D., F.R.C.P.C.
Deputy Psychiatrist-in-Chief, Head, Mood and Anxiety Disorders Program, Sunnybrook Health Sciences Centre; Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Mark Sinyor, M.Sc., M.D., F.R.C.P.C.
Psychiatrist, Sunnybrook Health Sciences Centre; Assistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Adriane M. Soehner, Ph.D.
Assistant Professor, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Eva Solé, M.D.
Psychiatrist, Department of Psychiatry and Psychology, Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
Trisha Suppes, M.D., Ph.D.
Professor, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California; VA Palo Alto Health Care System, Palo Alto, California
Holly A. Swartz, M.D.
Professor, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Eduard Vieta, M.D., Ph.D.
Professor of Psychiatry, Chair, Department of Psychiatry and Psychology, Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
Katherine L. Wisner, M.D., M.S.
Norman and Helen Asher Professor of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology; Director, Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Mark Zimmerman, M.D.
Professor of Psychiatry and Human Behavior, Brown University; Director of Outpatient Psychiatry and Partial Hospital Program, Rhode Island Hospital, Providence, Rhode Island
Disclosure of Competing Interests
The following contributors to this book have indicated a financial interest in or other affiliation with a commercial supporter, a manufacturer of a commercial product, a provider of a commercial service, a nongovernmental organization, and/or a government agency, as listed below:
Boris Birmaher, M.D.—Research funding: National Institute of Mental Health; Royalties: Lippincott Williams & Wilkins, Random House, UpToDate
Marina Garriga, M.D.—Grants and/or consultant/advisor: Centro de Investigación Biomédica en Red de salud Mental (CIBERSAM), FEDER, Ferrer, Instituto de Salud Carlos III, Janssen, Lundbeck
Susan L. McElroy, M.D.—Principal investigator or co-investigator on research studies sponsored by: Allergan, Brainsway, Marriott Foundation, Myriad, National Institute of Mental Health, Novo Nordisk, Shire, Sunovion; Consultant or scientific advisory board: Bracket, F. Hoffmann-La Roche, MedAvante, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Shire, Sunovion; Patents: Inventor on U.S. Patent 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson Pharmaceutical Research and Development, L.L.C., which has exclusive rights under the patent
Melvin McInnis, M.D.—Research support: National Institute of Mental Health (R21 MH114835), Prechter Bipolar Research Fund, Richard Tam Foundation, University of Michigan Depression Center; the author has consulted with Janssen and Otsuka Pharmaceuticals
Eydie L. Moses-Kolko, M.D.—Site Principal Investigator for Sage Pharmaceuticals trial of brexanolone for treatment of postpartum depression (period of study approximately November 1, 2016, to November 1, 2017)
Ayal Schaffer, M.D., F.R.C.P.C.—Research grants: American Foundation for Suicide Prevention; Canadian Institute of Health Research; Ontario Mental Health Foundation; Ontario Ministry of Health and Long-Term Care (IMPACT Award); Honoraria of other fees: Allergan, Asofarma, Lundbeck, Sunovion
Eva Solé, M.D.—Grants and/or consultant/advisor: Centro de Investigación Biomédica en Red de salud Mental (CIBERSAM), Instituto de Salud Carlos III
Holly A. Swartz, M.D.—Grant support: Myriad Genetics, National Institute of Mental Health; Consultant: Myriad Genetics; Royalties: UpToDate
Eduard Vieta, M.D., Ph.D.—Grants and consultant/advisor/CME speaker: AB-Biotics, Actavis, Allergan, AstraZeneca, Bristol-Myers Squibb, Ferrer, Forest Research Institute, Geodon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, Telefónica, Brain and Behavior Foundation, Spanish Ministry of Science and Innovation (Centro de Investigación Biomédica en Red de salud Mental; CIBERSAM), Seventh European Framework Programme (ENBREC), Stanley Medical Research Institute
The following contributors to this book have indicated no competing interests to disclose:
Crystal T. Clark, M.D., M.Sc.
Sarah DeBrunner, M.D.
Anna Manelis, Ph.D.
Manivel Rengasamy, M.D.
Trisha Suppes, M.D., Ph.D.